A PLACEBO-CONTROLLED CROSSOVER STUDY OF KETANSERIN IN ELDERLY HYPERTENSIVE PATIENTS

被引：5

作者：

MCCARTHY, ST ^{[1
]}

MCCARTHY, GL ^{[1
]}

JOHN, SM ^{[1
]}

GOULD, SE ^{[1
]}

机构：

[1] RADCLIFFE INFIRM,DEPT GERIATR MED,OXFORD OX2 6HE,ENGLAND

来源：

CARDIOVASCULAR DRUGS AND THERAPY | 1990年 / 4卷

关键词：

efficacy tolerability; elderly hypertensives; ketanserin;

D O I：

10.1007/BF00053441

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The results of the European Working Party for Hypertension in the Elderly Study showed that treatment of high blood pressure reduced the morbidity and mortality from strokes and myocardial infarction and reduced the incidence of heart failure in elderly patients. The largest number of hypertensive patients are elderly, and it is in this group of patients that the maximum benefit of treatment might be expected. The present study was designed to study in detail the efficacy and tolerability of ketanserin in an elderly population. Seventeen elderly (> 70 years) patients with a lying systolic blood pressure of 160 mmHg and/or a diastolic blood pressure of ≥ 90 mmHg were included in the study. For the 12 patients who completed the study, the mean blood pressure was significantly reduced on ketanserin compared with placebo (p<0.001) in the supine and erect positions. The mean net changes in blood pressure after 8 weeks were 21/17 mmHg and 23/16 mmHg erect. Heart rate was also significantly reduced (p<0.001) by a mean of 8 beats/min lying and 9 beats/min erect. Analysis of ambulatory 24-hour ECG tapes showed no significant effect of ketanserin on heart rhythms. Ketanserin therapy had no significant effect on routine hematology, plasma electrolytes, biochemistry, or urinalysis. Total exchangeable sodium and potassium and body weight were also unchanged. On ketanserin treatment, the overall quality of life score was significantly improved (p=0.002; analysis of variance on log transformed data) compared with the placebo phase. © 1990 Kluwer Academic Publishers.

引用

页码：115 / 117

页数：3

共 10 条

[1]

Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial, Lancet, 1, pp. 1349-1354, (1985)

[2]

Tuck M.L., Clinical care of the ageing hypertensive patient, J Cardiovasc Pharmacol, 12, pp. S40-S48, (1988)

[3]

Vanhoutte P., Amery A., Birkenhager W., Et al., Serotonergic mechanisms in hypertension. Focus on the effects of ketanserin, Hypertension, 11, 2, pp. 111-133, (1988)

[4]

Rossendorff C., Murray G.D., Ketanserin versus metoprolol and hydrochlorothiazide in essential hypertension: Only ketanserin's hypotensive effect is age related, J Hypertens, 4, pp. S109-S111, (1986)

[5]

Turner J.F., Gould S.E., Wellburn P.J., Et al., The effect of antihypertensive treatment on the assessment of wellbeing in a general practice population, J Hypertens, 5, pp. S529-S531, (1987)

[6]

McGourty J.C., Silas J.H., Cowen K.J., Controlled trial of ketanserin in hypertension, Br J Clin Pharmacol, 20, pp. 37-40, (1985)

[7]

Cameron H.A., Raay L.E., Ketanserin in essential hypertension: A double blind placebo controlled study, Postgrad Med J, 61, pp. 583-586, (1985)

[8]

Randomized trial of ketanserin for prevention of atherosclerotic complications, Br Med J, 298, pp. 424-430, (1989)

[9]

Turner J.F., Gould S.E., Welburn P.J., Et al., The effect of antihypertensive treatment on the assessment of well-being in a general practice population, J Hypertens, 5, pp. S529-S531, (1987)

[10]

Korlipara K., Gould S.E., Taylor N.A., Et al., Comparative trial of ketanserin or bendrofluazide as add-on therapy in hypertensive patients uncontrolled on a β-blocker alone, Drugs, 36, pp. 130-134, (1988)

← 1 →